Ras Inhibitor

Ras Inhibitors (421):

Cat. No.	Product Name	Effect	Purity

HY-147634

KRAS G12C inhibitor 53	Inhibitor
KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.

HY-168013

KRASG12C IN-14	Inhibitor
KRASG12C IN-14 (compound 15) is an inhibitor targeting the KRAS G12C mutation. KRASG12C IN-14 inhibits CYPA-dependent KRAS-BRAF with an IC₅₀ of 0.002 μM. KRASG12C IN-14 inhibits ERK phosphorylation in NCI-H358 cells with an IC₅₀ of 0.002 μM.

HY-142490

KRAS G12C inhibitor 33	Inhibitor
KRAS G12C inhibitor 33 is a KRAS G12C inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer.

HY-173047

KRASG12C IN-15	Inhibitor
KRASG12C IN-15 (Compound 21) is the orally active inhibitor for KRAS^G12C, and inhibits SOS1-mediated GDP/GTP exchange with an IC₅₀ of 19 nM. KRASG12C IN-15 inhibits the phosphorylation of ERK with IC₅₀ of 0.051 μM. KRASG12C IN-15 inhibits the cell viability of KRAS^G12C mutated MIA PaCa-2 with IC₅₀ of 0.023 μM. KRASG12C IN-15 exhibits antitumor effect in MIA PaCa-2 xenograft mouse models.

HY-162321

ZINC57632462	Inhibitor
ZINC57632462 (ACA-6) is a non-covalent allosteric KRAS inhibitor. ZINC57632462 disrupts nucleotide exchange and inhibits RAS-effector interaction. ZINC57632462 can be used for the research of cancer.

HY-161236

KRAS ligand 4	Inhibitor
KRAS ligand 4 (compound 2) is a bifunctional molecular glue degrader based on SOS1. KRAS ligand 4 reduces downstream signaling markers pERK and pS6 and displays anti-additional activity in cells with multiple KRAS mutations.

HY-P10832

ATWLPPRAANLLMAAS	Inhibitor
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis..

HY-P10847

KS-58	Inhibitor
KS-58 is a KRpep-2d (HY-P3277) derivative. KS-58 is a K-Ras (G12D) inhibitory peptide that selectively binds K-Ras. KS-58 can enter cells and block intracellular Ras interaction with effector proteins. KS-58 inhibits the proliferation of tumor cells and has antitumor activity.

HY-145017

KRAS G12C inhibitor 20	Inhibitor
KRAS G12C inhibitor 20 is a KRAS G12C inhibitor extracted from patent CN112694475A, example 1.

HY-168919

KRASG12C IN-16	Inhibitor
KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRAS^G12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer.

HY-143603

KRAS G12D inhibitor 10	Inhibitor
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34).

HY-159476

KRAS inhibitor-26	Inhibitor
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research.

HY-148261

KRAS G12C inhibitor 56	Inhibitor
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC₅₀ of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research.

HY-145915

ZINC09659342	Inhibitor
ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction with an IC₅₀ of 3.6 μΜ.

HY-159475

KRAS inhibitor-25	Inhibitor
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine KRAS inhibitor, with an IC₅₀ of < 100 nM against KRas G12V, KRas WT and KRas G12R.

HY-164529

SJ-C1044	Inhibitor
SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC₅₀ values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2/KDR/Flk-1, TIE2, and CSF1R, with IC₅₀ values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer.

HY-160220S

KRAS inhibitor-23	Inhibitor
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research.

HY-119264

PRLX-93936	Inhibitor
PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma.

HY-120271

GGTI-297	Inhibitor
GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC₅₀ values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras.

HY-157067

KRAS G12C inhibitor 62	Inhibitor
KRAS G12C inhibitor 62 is a KRAS G12C inhibitor. KRAS G12C inhibitor 62 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1).

Name
Email *

	Sorry, but the email address you supplied was invalid.